Logo Logo

Publications by Tiseo, M.

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 3.

Journal article

Ou, S.-H. I.; Tiseo, M.; Camidge, R.; Ahn, M.-J.; Huber, R. M.; Hochmair, M. J.; Kim, S-W.; West, H. L.; Reckamp, K. L.; Molina, J. R.; Liu, G.; Delmonte, A.; Viteri, S.; Bearz, A.; Summers, Y.; Reichmann, W.; Kerstein, D.; Gettinger, S. N.; Kim, D.-W. (2017): Intracranial efficacy of brigatinib (BRG) in patients (Pts) With crizotinib (CRZ)-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and baseline CNS metastases. In: Annals of Oncology, Vol. 28

Tiseo, M.; Huber, R. M.; Hochmair, M. J.; Bazhenova, L. A.; Ou, S.-H. I.; Reichmann, W.; Haney, J.; Kerstein, D.; Camidge, D. R.; Gettinger, S. N. (2017): Brigatinib in ALK plus NSCLC pts with intracranial CNS metastases in 2 clinical trials. In: Annals of Oncology, Vol. 28

Kim, D.; Tiseo, M.; Ahn, M.; Reckamp, K.; Hansen, K. Holmskov; Kim, S.; Huber, R.; West, H.; Groen, H.; Hochmair, M.; Leighl, N.; Gettinger, S.; Langer, C.; Paz-Ares Rodriguez, L.; Smit, E.; Reichmann, W.; Kerstein, D.; Haluska, F.; Camidge, D. (2016): Brigatinib (BRG) in Crizotinib (CRZ)-Refractory ALK plus Non-Small Cell Lung Cancer (NSCLC): efficacy and safety results from ALTA, a pivotal randomized phase 2 Trial. In: Annals of Oncology, Vol. 27: iv4-

This list was generated on Thu Jul 16 00:04:17 2020 CEST.